Background: GLP-1 RAs are an injectable class of medications with demonstrated weight loss in clinical trials. However, weight changes related to GLP-1RA use have not been well-characterized in a real-world setting. Further, there are limited real-world data on patient adherence to and discontinuation of GLP-1RAs.

Methods: Using the UK Clinical Practice Research Datalink (CPRD) database (2010-2016), we conducted a retrospective cohort study of UK T2D patients ≥ 18 years of age initiating GLP-1RAs to evaluate one-year weight change, as well as GLP-1 RA adherence and discontinuation. Included patients initiated GLP-1RA as monotherapy or as dual therapy with metformin. GLP-1 RA adherence was assessed using the proportion of days covered (PDC) among all GLP-1 RA initiators with two or more prescriptions. Discontinuation was defined as any GLP-1 RA therapy gap >90 days during follow-up.

Results: 589 patients met the study criteria; Female: 56.4%, median age: 54 years, and median BMI: 41.2 kg/m2. The median one-year weight change was -3.1 kg; 72.1% of patients experienced weight loss while the rest of patients reported weight gain. Furthermore, only 32.6% of patients had a weight loss that is typically considered clinically-meaningful (≥5%). In terms of adherence, 64.5% of patients were considered adherent (PDC ≥80%) while 45.2% of patients discontinued GLP-1RA by 1 year.

Conclusion: Less than one-third of patients initiating GLP-1RA achieved ≥5% weight loss. Further, approximately one-third of patients were non-adherent to therapy and nearly half discontinued treatment within a year. Further investigation on the impact of GLP-1 RA adherence and discontinuation on real-world effectiveness is warranted.


T. Weiss: Employee; Self; Merck & Co., Inc. K. Iglay: Employee; Self; Merck & Co., Inc. Stock/Shareholder; Self; Merck & Co., Inc. R.D. Carr: Employee; Self; Merck & Co., Inc. Speaker's Bureau; Spouse/Partner; Eli Lilly and Company, Merck & Co., Inc. A.P. Mishra: None. L. Yang: Employee; Self; Bristol-Myers Squibb Company, Merck & Co., Inc. S. Rajpathak: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at